KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

We report on a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the disease had failed to respond to a combination of a PI3K...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Shumei, McFall, Thomas, Takahashi, Kenta, Bamel, Kasey, Ikeda, Sadakatsu, Eskander, Ramez N., Plaxe, Steven, Parker, Barbara, Stites, Edward, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018312/
https://www.ncbi.nlm.nih.gov/pubmed/33528846
http://dx.doi.org/10.1002/onco.13702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018312/
https://www.ncbi.nlm.nih.gov/pubmed/33528846
http://dx.doi.org/10.1002/onco.13702

Ejemplares similares